<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02899455</url>
  </required_header>
  <id_info>
    <org_study_id>HM-ALRO-301</org_study_id>
    <nct_id>NCT02899455</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia</brief_title>
  <official_title>Efficacy and Safety of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia: A Randomized, Double-blind, Multicenter, Phase 3 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 3 study to evaluate efficacy and safety of Co-administered HGP0904, HGP0608 and
      HGP0816 in Patients with Hypertension and Dyslipidemia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a multi-center, double-blinded, randomized, phase 3 clinical trial
      to evaluate the efficacy and safety of Co-administered HGP0904, HGP0608 and HGP0816 in
      Patients with Hypertension and Dyslipidemia
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change from baseline in LDL-cholesterol at Week 8</measure>
    <time_frame>baseline and 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in sitDBP at Week 8</measure>
    <time_frame>baseline and 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in LDL cholesterol at Week 4</measure>
    <time_frame>baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in Total cholesterol, HDL cholesterol, Triglyceride at Week 4,8</measure>
    <time_frame>baseline, 4weeks and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sitDBP at Week 4</measure>
    <time_frame>baseline and 4weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sitSBP at week 4, 8</measure>
    <time_frame>baseline, 4weeks and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving LDL-cholesterol goals by cardiovascular risk category at Week 4, 8</measure>
    <time_frame>baseline, 4weeks and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving Blood Pressure control by cardiovascular risk category at Week 4, 8</measure>
    <time_frame>baseline, 4weeks and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving LDL-cholesterol goals and Blood Pressure control by cardiovascular risk category at Week 4, 8</measure>
    <time_frame>baseline, 4weeks and 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Hypertension</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HGP0904 + HGP0608 + HGP0816, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HGP0904 placebo + HGP0608 + HGP0816, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HGP0904 + HGP0608 + HGP0816 placebo, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP0904</intervention_name>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_label>Active Comparator2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP0608</intervention_name>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_label>Active Comparator1</arm_group_label>
    <arm_group_label>Active Comparator2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP0816</intervention_name>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_label>Active Comparator1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP0904 Placebo</intervention_name>
    <arm_group_label>Active Comparator1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP0816 Placebo</intervention_name>
    <arm_group_label>Active Comparator2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 19 ≤ age ≤ 75

          2. at Visit 1 1) BP: sitDBP ≥ 90mmHg 2) Cholesterol : LDL-C ≤ 250mg/dL, TG &lt; 400mg/dL

          3. at Visit 2 : after TLC (after 4weeks) 1) BP: 80 mmHg ≤ sitDBP &lt; 110mmHg 2) Cholesterol
             : following risk category (Cardiovascular Risk category) A : CHD risk factor 0 - 1,
             160mg/dL ≤ LDL-C ≤ 250mg/dL B①: CHD risk factor≥2 and 10 year risk &lt;10%, 160mg/dL ≤
             LDL-C ≤ 250mg/dL B②: CHD risk factor≥2 and 10 year risk =10-20%, 130mg/dL ≤ LDL-C ≤
             250mg/dL C : CHD/CHD risk equivalents* or 10 year risk&gt;20 ,100mg/dL ≤ LDL-C ≤ 250mg/dL
             3) TG &lt; 400mg/dL 4. Patients understood the contents and purpose of this trial and
             signed informed consent form

        Exclusion Criteria:

          1. At Visit 1, BP difference SBP ≥20mmHg or DBP ≥10mmHg

          2. Tolerance or Hypersensitivity Angiotensin II receptor blocker or HMG-CoA. reductase
             inhibitor, Calcium channel blocker(dihydropyridine) or Multi-drug allergy

          3. Fibromyalgia, myopathy, rhabdomyolysis or acute myopathy or medical history of adverse
             effect to statin

          4. CPK normal range ≥ 3times

          5. Uncontrolled primary hypothyroidism(TSH normal range ≥ 2 times)

          6. Renal disease or suspected renal disease (Scr ≥ 2mg/dL, AST or ALT≥2 times)

          7. Active gout or hyperuricemia(at Visit 1, uric acid &gt; 9mg/dL)

          8. IDDM or uncontrolled diabetes mellitus (HbA1c&gt;9%)

          9. ventricular arrhythmia

         10. medical history

               -  severe cerebrovascular disease within 6 months (cerebral infarction, cerebral
                  hemorrhage), hypertension

               -  encephalopathy, transient cerebral ischemic attack(TIA)

               -  severe heart disease(heart failure of NYHA class III-IV), valvular disease of
                  heart or myocardial infarction and unstable angina

               -  angioplasty or coronary artery bypass graft(CABG) surgery within 6months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>23 institutions including Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>September 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2016</study_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Hyperlipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>August 24, 2017</submitted>
    <returned>March 19, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

